All In Biotech

Drug Trial Radar · NCT06782555

A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab

A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab in Patients With Advanced Solid Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

71

Planned (sponsor's estimate)

Start

Jan 8, 2025

Primary completion

Oct 2027

Study completion Jan 2028

Sponsor

Lead sponsor
ImmunoGenesisIndustry
Sponsor type
Industry
Collaborators
Agenus Inc.
First posted
Jan 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).

Conditions

  • Metastatic Prostate Cancer
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Pancreatic Cancer

Interventions

  • EvofosfamideDrug

    Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

  • ZalifrelimabDrug

    Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

  • BalstilimabDrug

    Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events including dose-limiting toxicitiesTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.